Genedrive MT-RNR1 ID Kit to detect genetic variation and protect hearing in babies: early value appraisal.
The Genedrive MT-RNR1 ID Kit has potential benefits in identifying babies at risk of hearing loss from aminoglycoside due to the MT-RNR1 m.1555A>G variant, allowing for alternative antibiotics to be used instead. However, managing the risk of early access is important, including ensuring timely antibiotics, avoiding unnecessary use of alternative antibiotics, and confirming positive results. The economic evidence suggests cost-effectiveness, but upfront costs may be high. Data should be generated in centers with babies from different ethnicities to promote equality.
Recent Posts
HIV Therapy Advancements: Promising Results from Bictegravir/Lenacapavir Combination Trial
Breakthrough Single-Tablet Regimen Drives HIV Therapy Advancements
Gilead Sciences has announced promising topline results from the Phase 3 ARTISTRY-1 trial, demonstrating that an investigational single-tablet regim...
Weight Loss: Advances in Hormone-Based Obesity Treatments
Advances in Hormone-Based Pharmacotherapies for Obesity
Hormone-based obesity treatments are improving the approach to weight management by targeting the body's neurometabolic systems. A recent
NICE NHS Prioritization: A Strategic Shift to Address Healthcare Challenges
NICE's Unified Prioritization Roadmap
NICE NHS prioritization has led to a new, unified framework and board that will tackle emerging healthcare innovations while managing finite assessment capacity. The approach focuses on high-impact areas, including mental health, early cancer detect...